A detailed history of Bank Hapoalim Bm transactions in Novo Nordisk A S stock. As of the latest transaction made, Bank Hapoalim Bm holds 9,110 shares of NVO stock, worth $966,844. This represents 0.16% of its overall portfolio holdings.

Number of Shares
9,110
Previous 9,710 6.18%
Holding current value
$966,844
Previous $1.39 Million 21.72%
% of portfolio
0.16%
Previous 0.2%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$119.07 - $145.42 $71,442 - $87,251
-600 Reduced 6.18%
9,110 $1.09 Million
Q2 2024

Jul 23, 2024

SELL
$122.71 - $146.91 $61,355 - $73,455
-500 Reduced 4.9%
9,710 $1.39 Million
Q1 2024

May 01, 2024

SELL
$102.11 - $135.92 $137,848 - $183,491
-1,350 Reduced 11.68%
10,210 $1.31 Million
Q4 2023

Jan 22, 2024

SELL
$87.78 - $105.45 $237,006 - $284,715
-2,700 Reduced 18.93%
11,560 $1.2 Million
Q3 2023

Oct 24, 2023

BUY
$90.94 - $199.54 $593,838 - $1.3 Million
6,530 Added 84.48%
14,260 $1.3 Million
Q2 2023

Jul 26, 2023

SELL
$155.98 - $172.65 $116,984 - $129,487
-750 Reduced 8.84%
7,730 $1.25 Million
Q1 2023

Apr 25, 2023

SELL
$132.34 - $159.14 $177,335 - $213,247
-1,340 Reduced 13.65%
8,480 $1.35 Million
Q3 2022

Nov 08, 2022

SELL
$95.28 - $116.93 $19,056 - $23,386
-200 Reduced 2.0%
9,820 $978,000
Q1 2022

Apr 28, 2022

SELL
$93.1 - $112.54 $200,165 - $241,961
-2,150 Reduced 17.67%
10,020 $1.11 Million
Q4 2020

Feb 03, 2021

SELL
$63.89 - $73.8 $44,723 - $51,660
-700 Reduced 5.44%
12,170 $850,000
Q3 2020

Nov 12, 2020

SELL
$63.69 - $70.22 $82,797 - $91,286
-1,300 Reduced 9.17%
12,870 $894,000
Q4 2019

Feb 03, 2020

BUY
$49.86 - $58.26 $62,325 - $72,825
1,250 Added 9.67%
14,170 $820,000
Q3 2017

Nov 07, 2017

BUY
$41.15 - $49.22 $308,625 - $369,150
7,500 Added 138.38%
12,920 $622,000
Q2 2017

Aug 11, 2017

BUY
N/A
5,420
5,420 $232,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $240B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Bank Hapoalim Bm Portfolio

Follow Bank Hapoalim Bm and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Hapoalim Bm, based on Form 13F filings with the SEC.

News

Stay updated on Bank Hapoalim Bm with notifications on news.